Investigational drug · Phase 3
TNM001
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Respiratory Syncytial Virus Infections.
Phase 3Last checked: Nov 19, 2026Latest source record: Mar 5, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
3
Any phase or sponsor naming "TNM001"
First trial start
2023
Sep 11, 2023
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TNM001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Respiratory Syncytial Virus Infections
Approved drugs for the same conditions: RSV · Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "TNM001" as an intervention, largest first.
- A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in InfantsPivotal-lookingCompleted
Zhuhai Trinomab Pharmaceutical Co., Ltd.Industry
NCT06083623 · 2,282 participants · Start Sep 11, 2023 · Primary completion Jun 16, 2025
Drug: TNM001; placebo · For: Respiratory Syncytial Virus Infections
Sites: Beijing, China; Chongqing, China; Xiamen, China · 39 sites in all
- A Sudy to Evaluate the Efficacy and Safety of TNM001 in High-risk InfantsPivotal-lookingCompleted
Zhuhai Trinomab Pharmaceutical Co., Ltd.Industry
NCT06710925 · 315 participants · Start Nov 28, 2024 · Primary completion Jul 27, 2025
Drug: TNM001; placebo · For: Respiratory Syncytial Virus Infections
Sites: Chengdu, China; Chongqing, China
Zhuhai Trinomab Pharmaceutical Co., Ltd.Industry
NCT05630573 · 31 participants · Start Oct 25, 2022 · Primary completion Jun 30, 2023
Drug: TNM001; Placebo · For: Respiratory Syncytial Virus Infections
Sites: Shijiazhuang, China; Changsha, China; Linfen, China · 6 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Genetic variability of respiratory syncytial virus and its impact on monoclonal antibody binding sites: a national cross-sectional study during the 2023-2024 season.
Piralla A, Romano G, Acciarri C, et al. · Int Immunopharmacol 2025
Also in development for Respiratory Syncytial Virus Infections
- RSVPreF3 OA investigational vaccinePhase 33 trials
GSK · Respiratory Syncytial Virus Infections
- RSVPreF3 OA vaccinePhase 32 trials
GSK · Respiratory Syncytial Virus Infections
- ZiresovirAK0529Phase 32 trials
Shanghai Ark Biopharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections, Respiratory Synctial Virus Infections
- Adjuvanted RSVPreF3 vaccinePhase 22 trials
GSK · Cardiovascular Disease, Respiratory Syncytial Virus Infections
- BLB-201PIV5-vectored RSV VaccinePhase 21 trial
Blue Lake Biotechnology Inc. · Respiratory Syncytial Virus Infections
- SYH2066Phase 21 trial
CSPC Ouyi Pharmaceutical Co., Ltd. · Respiratory Syncytial Virus Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.